hfpef semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials Semaglutide and NT-proBNP in Obesity-Related
Description
These results match the efficacy of injectable PCSK9 inhibitors like Amgen's Repatha, Regeneron's Praluent, and Novartis' Leqviobut with critical advantages
Les changes concernant le paiement et les frais de douane se poursuivent ensuite directement via WhatsApp
The associated medical costs from overweight and obesity are estimated to be RMB 418 billion
PMID 23397029
After nine years the tight BP control group had a 34% reduction in the deterioration of retinopathy (P=0.0004) and a 47% reduced risk (P=0.004) of deterioration in visual acuity
